Stockscreener 앱 받기
55.26
2.40%
-1.36
전일 마감가:
$56.62
열려 있는:
$56.46
하루 거래량:
13.65M
Relative Volume:
0.91
시가총액:
$112.50B
수익:
$48.03B
순이익/손실:
$6.05B
주가수익비율:
18.66
EPS:
2.9615
순현금흐름:
$15.30B
1주 성능:
-1.07%
1개월 성능:
+1.90%
6개월 성능:
+17.15%
1년 성능:
-1.99%
1일 변동 폭
$55.10
$56.56
1주일 범위
$55.10
$57.04
52주 변동 폭
$42.52
$63.33
브리스톨 마이어스 스퀴브 Stock (BMY) Company Profile
명칭
Bristol Myers Squibb Co
전화
(609) 252-4621
주소
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
BMY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
55.26 | 115.26B | 48.03B | 6.05B | 15.30B | 2.9615 |
|
LLY
Lilly Eli Co
|
1,038.40 | 924.53B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
218.66 | 529.01B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
214.35 | 383.08B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVO
Novo Nordisk Adr
|
62.33 | 253.81B | 46.69B | 15.29B | 9.25B | 3.4329 |
|
NVS
Novartis Ag Adr
|
144.34 | 274.68B | 54.45B | 14.42B | 17.15B | 7.333 |
브리스톨 마이어스 스퀴브 Stock (BMY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 업그레이드 | UBS | Neutral → Buy |
| 2025-12-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-12-12 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Perform |
| 2025-08-05 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2025-04-22 | 개시 | Piper Sandler | Overweight |
| 2024-12-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-13 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-07-29 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-03-11 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2024-02-06 | 다운그레이드 | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-11-15 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-02 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2023-10-27 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-07-14 | 개시 | HSBC Securities | Reduce |
| 2023-07-10 | 개시 | SVB Securities | Market Perform |
| 2023-06-28 | 개시 | Daiwa Securities | Outperform |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-01-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-11-18 | 개시 | Credit Suisse | Neutral |
| 2022-10-10 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-09-14 | 다운그레이드 | Berenberg | Buy → Hold |
| 2022-06-03 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | 재개 | Morgan Stanley | Underweight |
| 2021-12-17 | 개시 | Goldman | Buy |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-01 | 다운그레이드 | Argus | Buy → Hold |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-04-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | 업그레이드 | Truist | Hold → Buy |
| 2020-11-16 | 업그레이드 | Societe Generale | Hold → Buy |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-11-06 | 다운그레이드 | Gabelli & Co | Buy → Hold |
| 2020-10-19 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2020-07-28 | 개시 | Raymond James | Outperform |
| 2020-04-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-01-06 | 재개 | Citigroup | Buy |
| 2019-12-13 | 업그레이드 | Argus | Hold → Buy |
| 2019-11-22 | 재개 | Morgan Stanley | Equal-Weight |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-08-14 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | 개시 | Goldman | Buy |
| 2019-05-20 | 다운그레이드 | Argus | Buy → Hold |
| 2019-05-03 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-05-03 | 재개 | JP Morgan | Overweight |
| 2019-01-15 | 업그레이드 | Societe Generale | Sell → Buy |
| 2018-10-22 | 다운그레이드 | Citigroup | Buy → Neutral |
모두보기
브리스톨 마이어스 스퀴브 주식(BMY)의 최신 뉴스
Bristol-Myers Squibb Co (NYSE:BMY): A High-Yield Dividend Stock With a Path to Growth - Chartmill
Novo Nordisk, BioMarin make AI moves; Bristol Myers welcomes neurology exec from Eisai - Endpoints News
Another ADC foray for Bristol Myers Squibb - The Pharma Letter
Campbell & CO Investment Adviser LLC Has $5.81 Million Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
The Bull Case For Bristol-Myers Squibb (BMY) Could Change Following Camzyos’ Phase 3 Adolescent oHCM Win - simplywall.st
Bernstein Sticks to Its Hold Rating for Bristol-Myers Squibb (BMY) - The Globe and Mail
Immunai and Bristol Myers Squibb turn to AI to decode immune responses in clinical trials - CTech
Stephens Inc. AR Raises Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb (NYSE:BMY) Trading 1.9% Higher After Analyst Upgrade - MarketBeat
Rep. Gilbert Ray Cisneros, Jr. Buys Bristol Myers Squibb Company (NYSE:BMY) Shares - MarketBeat
Bristol-Myers Squibb Reports Positive Phase 3 SCOUT-HCM Results for Camzyos in Adolescent Patients - Finviz
Bristol Says New Version of Opdivo on Track to Meet Target - Bloomberg.com
Leerink Partners Remains a Buy on Bristol-Myers Squibb (BMY) - The Globe and Mail
Manning & Napier Advisors LLC Lowers Stake in Bristol Myers Squibb Company $BMY - MarketBeat
[Latest] Global T-Cell Engagers Market Size/Share Worth USD 18.8 Billion by 2034 at a 21.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
Pharmaceutical research and development pipeline - Bristol Myers Squibb
Leerink Partners Raises Price Target for Bristol-Myers Squibb (B - GuruFocus
Leerink Partners Issues Positive Forecast for Bristol Myers Squibb (NYSE:BMY) Stock Price - MarketBeat
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock - Yahoo Finance
Bristol Myers Squibb Company $BMY Position Raised by Sumitomo Mitsui Trust Group Inc. - MarketBeat
JPM26: BMS places confidence in core pipeline to weather 2030 patent cliff - Pharmaceutical Technology
Bristol-Myers Squibb stock price target raised to $60 from $54 at Leerink - Investing.com
Bristol Myers Squibb Company $BMY Shares Sold by GRIMES & Co WEALTH MANAGEMENT LLC - MarketBeat
Worldwide locations - Bristol Myers Squibb
JPM26: US biotech’s ‘Sputnik moment,’ Pfizer’s obesity ambitions and Bristol Myers’ big year - BioPharma Dive
AbbVie Becomes Latest To License PD-1xVEGF Bispecific In Growing Field - Citeline News & Insights
JPM26: Bristol Myers CEO to 'cast a broad net' as business development remains a top priority - Fierce Pharma
Bristol Myers Squibb CEO Outlines 2030 Growth Strategy Focused on Oncology, Immunology, and Cardiovascular Expansion at JP Morgan Healthcare Conference - geneonline.com
Bristol-Myers Squibb Stock Under Pressure: Is This Deep-Value Pharma Name Finally Near a Turning Poi - AD HOC NEWS
Bristol-Myers Squibb Company (BMY) Releases New Investor Presentation - GuruFocus
Bristol-Myers Squibb Advances Liver Cancer Combo as Key Trial Reaches Completion - TipRanks
Scotiabank Raises Bristol-Myers (BMY) PT to $60 Citing Catalyst-Rich 2026 Growth - Insider Monkey
What You Need To Know Ahead of Bristol-Myers Squibb's Earnings Release - Barchart.com
Bristol Myers Squibb’s Camzyos shows positive results in adolescent oHCM trial - Investing.com
BMY Reports Positive Results from Phase 3 SCOUT-HCM Trial - GuruFocus
First Horizon Corp Acquires New Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb: A Pivotal Year Ahead as Sentiment Shifts - AD HOC NEWS
Nepsis Inc. Decreases Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Lecap Asset Management Ltd. Sells 19,756 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
How Recent Developments Are Shaping The Bristol Myers Squibb (BMY) Investment Story - Yahoo Finance
Did UBS’s Pipeline-Driven Upgrade Just Shift Bristol-Myers Squibb’s (BMY) Investment Narrative? - Yahoo Finance
BMY Rallies 17.3% in Six Months: Buy, Sell or Hold the Stock? - TradingView — Track All Markets
Scotiabank raises Bristol-Myers Squibb stock price target to $60 on growth - Investing.com
Next Level Private LLC Has $2.54 Million Position in Bristol Myers Squibb Company $BMY - MarketBeat
Scotiabank Adjusts Price Target on Bristol-Myers Squibb to $60 From $53, Maintains Sector Perform Rating - marketscreener.com
Privacy notice center - Bristol Myers Squibb
What RSI levels show for Bristol Myers Squibb Company (BRM) stockStock Surge & AI Enhanced Execution Alerts - ulpravda.ru
Is Bristol Myers Squibb Company Celegne Contingent stock attractive post correctionMarket Performance Report & Consistent Growth Equity Picks - ulpravda.ru
Will Bristol Myers Squibb Company stock outperform foreign stocksJuly 2025 PostEarnings & Weekly High Return Stock Forecasts - ulpravda.ru
The Escalator: Argenx, Gilead Sciences, Bristol Myers Squibb and more - Medical Marketing and Media
SG Americas Securities LLC Has $75.53 Million Stake in Bristol Myers Squibb Company $BMY - MarketBeat
브리스톨 마이어스 스퀴브 (BMY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.85%
3.01%
자본화:
|
볼륨(24시간):